Last $53.95 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical ind ltd (TEVJF) Snapshot

Open
$53.95
Previous Close
$53.95
Day High
$53.95
Day Low
$53.95
52 Week High
08/1/14 - $53.95
52 Week Low
11/18/13 - $38.20
Market Cap
46.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
854.0M
EX-Date
08/21/14
P/E TM
--
Dividend
$485.66
Dividend Yield
2.48%
Current Stock Chart for TEVA PHARMACEUTICAL IND LTD (TEVJF)

teva pharmaceutical ind ltd (TEVJF) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Founded in 1901

teva pharmaceutical ind ltd (TEVJF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical ind ltd (TEVJF) Key Developments

Teva Pharmaceutical Industries Initiates Laquinimod Clinical Trial in Huntington's Disease

Active Biotech announced that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington's disease.

Teva Pharmaceutical Industries Limited Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of Fiscal 2014

Teva Pharmaceutical Industries Limited announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced net revenues of $5,045 million compared to $4,924 million for the same period a year ago. Operating income was $925 million compared to operating loss of $586 million for the same period a year ago. Income before income taxes was $847 million compared to loss before income taxes of $675 million for the same period a year ago. Net income was $745 million compared to net loss of $456 million for the same period a year ago. Net income attributable to the company was $748 million or $0.87 per diluted share compared to net loss attributable to the company of $452 million or $0.53 per diluted share for the same period a year ago. Non-GAAP net income attributable to the company was $1,054 million compared to $1,018 million for the same period a year ago. Non-GAAP earnings per share attributable to the company, diluted were $1.23 compared to $1.20 for the same period a year ago. Net cash provided by operating activities was $1,053 million compared to $875 million for the same period a year ago. Free cash flow, excluding net capital expenditures and dividends amounted to $583 million, an increase of $205 million from the second quarter of 2013. For the six months, the company announced net revenues of $10,046 million compared to $9,825 million for the same period a year ago. Operating income was $1,897 million compared to $288 million for the same period a year ago. Income before income taxes was $1,738 million compared to $24 million for the same period a year ago. Net income was $1,485 million compared to $170 million for the same period a year ago. Net income attributable to the company was $1,492 million or $1.75 per diluted share compared to $178 million or $0.21 per diluted share for the same period a year ago. Non-GAAP net income attributable to the company was $2,092 million compared to $1,978 million for the same period a year ago. Non-GAAP earnings per share attributable to the company, diluted were $2.45 compared to $2.32 for the same period a year ago. Net cash provided by operating activities was $1,951 million compared to $1,977 million for the same period a year ago. The company provided earnings guidance for the full year of fiscal 2014. The company announced that EPS guidance improved to $4.90 to $5.10 and revenue in the range of $19.8 billion to $20.8 billion, exclusive Copaxone scenario and to $4.50 to $4.80 in the generic Copaxone scenario.

Teva Pharmaceutical Industries Ltd Declares Quarterly Dividend, Payable on September 4, 2014

The Board of Directors of Teva Pharmaceutical Industries Ltd. at its meeting on July 29, 2014, declared a cash dividend for the second quarter of 2014 of ILS 1.21 per share (approximately 35.3 cents according to the rate of exchange on July 29, 2014). The record date will be August 21, 2014, and the payment date will be September 4, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVJF:US $53.95 USD 0.00

TEVJF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TEVJF.
View Industry Companies
 

Industry Analysis

TEVJF

Industry Average

Valuation TEVJF Industry Range
No financial data is available for TEVJF.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.